Truist lowered the firm’s price target on Alnylam (ALNY) to $505 from $515 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results among Biotech names. Though confident in robust y/y growth, the management cautioned for Q1 seasonal weakness in the US from typical payer dynamics and 2 less shipping weeks, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Seanergy, Arqit, Verisign, Alnylam, Lamb Weston Shake-Up
- BioCryst appoints Sandeep Menon as chief research and development officer
- Alnylam’s DemonsTTRate Study: Real-World Data Could Shift the ATTR-CM Investment Story
- Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26
- Alnylam presents new data on potential of zilebesiran for hypertension